XFRA ISIN CHANGE

Realtime	Geld	Brief	Zeit
	0,740	0,840	28.06.

Realtime

Geld

Brief

Zeit

0,740

0,840

28.06.

Einstellung Aufnahme
ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: Anmerkungen
CA3874371147 Granite REIT LP 03.10.2024 CA3874372053 Granite REIT LP 04.10.2024 Tausch 1:1
US86323X1063 Streamline Health Solutions Inc. 03.10.2024 US86323X2053 Streamline Health Solutions Inc. 04.10.2024 Tausch 15:1
US59564R7089 Biodexa Pharmaceuticals PLC 03.10.2024 US59564R8079 Biodexa Pharmaceuticals PLC 04.10.2024 Tausch 25:1
KYG9845F1090 LakeShore Biopharma Co. Ltd. 03.10.2024 KYG9845F2080 LakeShore Biopharma Co. Ltd. 04.10.2024 Tausch 10:1
US82655M1071 Sify Technologies Ltd. 03.10.2024 US82655M2061 Sify Technologies Ltd. 04.10.2024 Tausch 6:1
MHY8564W1030 Teekay Corp. 03.10.2024 BMG8726T1053 Teekay Corp. 04.10.2024 Tausch 1:1

Zeitenwende! 3 Uranaktien vor der Neubewertung

Ende Mai leitete US-Präsident Donald Trump mit der Unterzeichnung mehrerer Dekrete eine weitreichende Wende in der amerikanischen Energiepolitik ein. Im Fokus: der beschleunigte Ausbau der Kernenergie.

Mit einem umfassenden Maßnahmenpaket sollen Genehmigungsprozesse reformiert, kleinere Reaktoren gefördert und der Anteil von Atomstrom in den USA massiv gesteigert werden. Auslöser ist der explodierende Energiebedarf durch KI-Rechenzentren, der eine stabile, CO₂-arme Grundlastversorgung zwingend notwendig macht.

In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Unternehmen jetzt im Zentrum dieser energiepolitischen Neuausrichtung stehen, und wer vom kommenden Boom der Nuklearindustrie besonders profitieren könnte.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders von der Energiewende in den USA profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!

Hier klicken

Zeit	Aktuelle Nachrichten
Fr	Biodexa Pharmaceuticals Plc - 6-K, Report of foreign issuer
Fr	Biodexa Pharmaceuticals PLC: Results of Annual General Meeting	June 27, 2023 Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") Results of Annual General Meeting Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a clinical stage biopharmaceutical company developing... ► Artikel lesen
Mi	Biodexa Pharmaceuticals PLC: Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)	June 25, 2025 Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"),... ► Artikel lesen
Mo	Biodexa Pharmaceuticals PLC: Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP)	June 23, 2025 Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP) Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (Nasdaq: BDRX),... ► Artikel lesen
18.06.	Biodexa enrolls first patient in type 1 diabetes drug trial

Zeit

Aktuelle Nachrichten

Biodexa Pharmaceuticals Plc - 6-K, Report of foreign issuer

Biodexa Pharmaceuticals PLC: Results of Annual General Meeting

June 27, 2023 Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") Results of Annual General Meeting Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a clinical stage biopharmaceutical company developing...
► Artikel lesen

Biodexa Pharmaceuticals PLC: Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

June 25, 2025 Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"),...
► Artikel lesen

Biodexa Pharmaceuticals PLC: Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP)

June 23, 2025 Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP) Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (Nasdaq: BDRX),...
► Artikel lesen

18.06.

Biodexa enrolls first patient in type 1 diabetes drug trial

Zeit	Aktuelle Nachrichten
Sa	Granite Real Estate Investment Trust: Granite REIT to release Q2 2025 results Aug. 6
18.06.	Granite REIT declares CAD 0.2833 dividend
18.06.	Granite Real Estate Investment Trust: Granite REIT to pay 28.33-cent distribution July 15
17.06.	GRANITE REAL ESTATE INVESTMENT TRUST - 6-K, Report of foreign issuer
06.06.	Granite Real Estate Investment Trust: Granite REIT unitholders approve AGM resolutions

Zeit

Aktuelle Nachrichten

Granite Real Estate Investment Trust: Granite REIT to release Q2 2025 results Aug. 6

18.06.

Granite REIT declares CAD 0.2833 dividend

18.06.

Granite Real Estate Investment Trust: Granite REIT to pay 28.33-cent distribution July 15

17.06.

GRANITE REAL ESTATE INVESTMENT TRUST - 6-K, Report of foreign issuer

06.06.

Granite Real Estate Investment Trust: Granite REIT unitholders approve AGM resolutions

Zeit	Aktuelle Nachrichten
06.05.	LakeShore Biopharma Co., Ltd. - 6-K, Report of foreign issuer
25.03.	LakeShore Biopharma Co., Ltd. - 6-K, Report of foreign issuer
12.03.	LakeShore Biopharma Co., Ltd. - 6-K, Report of foreign issuer

Zeit

Aktuelle Nachrichten

06.05.

LakeShore Biopharma Co., Ltd. - 6-K, Report of foreign issuer

25.03.

LakeShore Biopharma Co., Ltd. - 6-K, Report of foreign issuer

12.03.

LakeShore Biopharma Co., Ltd. - 6-K, Report of foreign issuer

Zeit	Aktuelle Nachrichten
Di	SIFY TECHNOLOGIES LTD - 6-K, Report of foreign issuer
Di	Sify Technologies Limited: Sify Technologies announces the appointment of Dr. Ram Sewak Sharma as Director on the Board
10.06.	Sify Faces Nasdaq Non-Compliance After Board Resignation, Begins Search For New Independent Director
10.06.	SIFY TECHNOLOGIES LTD - 6-K, Report of foreign issuer
10.06.	Sify Technologies Limited: Sify Technologies Ltd. Announces Non-Compliance with Nasdaq Listing Requirements due to Resignation of a Director	CHENNAI, India, June 10, 2025 (GLOBE NEWSWIRE) -- Sify Technologies Ltd. (Nasdaq: Sify) (the "Company"), a leading integrated information communications technology (or ICT) Solutions and Services... ► Artikel lesen

Zeit

Aktuelle Nachrichten

SIFY TECHNOLOGIES LTD - 6-K, Report of foreign issuer

Sify Technologies Limited: Sify Technologies announces the appointment of Dr. Ram Sewak Sharma as Director on the Board

10.06.

Sify Faces Nasdaq Non-Compliance After Board Resignation, Begins Search For New Independent Director

10.06.

SIFY TECHNOLOGIES LTD - 6-K, Report of foreign issuer

10.06.

Sify Technologies Limited: Sify Technologies Ltd. Announces Non-Compliance with Nasdaq Listing Requirements due to Resignation of a Director

CHENNAI, India, June 10, 2025 (GLOBE NEWSWIRE) -- Sify Technologies Ltd. (Nasdaq: Sify) (the "Company"), a leading integrated information communications technology (or ICT) Solutions and Services...
► Artikel lesen

Zeit	Aktuelle Nachrichten
16.06.	STREAMLINE HEALTH SOLUTIONS INC. - 8-K, Current Report
16.06.	Streamline Health Solutions, Inc.: Streamline Health Reports Fiscal First Quarter 2025 Financial Results	ATLANTA, June 16, 2025 (GLOBE NEWSWIRE) -- Streamline Health Solutions, Inc. ("Streamline" or the "Company") (Nasdaq: STRM), a leading provider of solutions that enable healthcare providers to proactively... ► Artikel lesen
16.06.	STREAMLINE HEALTH SOLUTIONS INC. - 10-Q, Quarterly Report
30.05.	STREAMLINE HEALTH SOLUTIONS INC. - 10-K/A, Annual Report
29.05.	STREAMLINE HEALTH SOLUTIONS INC. - 8-K, Current Report

Zeit

Aktuelle Nachrichten

16.06.

STREAMLINE HEALTH SOLUTIONS INC. - 8-K, Current Report

16.06.

Streamline Health Solutions, Inc.: Streamline Health Reports Fiscal First Quarter 2025 Financial Results

ATLANTA, June 16, 2025 (GLOBE NEWSWIRE) -- Streamline Health Solutions, Inc. ("Streamline" or the "Company") (Nasdaq: STRM), a leading provider of solutions that enable healthcare providers to proactively...
► Artikel lesen

16.06.

STREAMLINE HEALTH SOLUTIONS INC. - 10-Q, Quarterly Report

30.05.

STREAMLINE HEALTH SOLUTIONS INC. - 10-K/A, Annual Report

29.05.

STREAMLINE HEALTH SOLUTIONS INC. - 8-K, Current Report

Zeit	Aktuelle Nachrichten
09.06.	Teekay Corporation: Teekay Group Publishes 2024 Sustainability Report
08.05.	Teekay Corporation Reports Fall In Q1 Bottom Line
07.05.	Teekay Corporation Bottom Line Drops In Q1
07.05.	Teekay declares $1.00 dividend
07.05.	TEEKAY CORP LTD - 6-K, Report of foreign issuer

Zeit

Aktuelle Nachrichten

09.06.

Teekay Corporation: Teekay Group Publishes 2024 Sustainability Report

08.05.

Teekay Corporation Reports Fall In Q1 Bottom Line

07.05.

Teekay Corporation Bottom Line Drops In Q1

07.05.

Teekay declares $1.00 dividend

07.05.

TEEKAY CORP LTD - 6-K, Report of foreign issuer

Unternehmen / Aktien	Kurs	%
BIODEXA PHARMACEUTICALS PLC ADR	0,876	-4,99 %
GRANITE REAL ESTATE INVESTMENT TRUST UTS	42,200	+1,11 %
LAKESHORE BIOPHARMA CO LTD	0,760	+1,33 %
SIFY TECHNOLOGIES LIMITED ADR	3,960	+0,51 %
STREAMLINE HEALTH SOLUTIONS INC	5,170	0,00 %
TEEKAY CORPORATION LTD	7,250	+0,69 %

Unternehmen / Aktien

Kurs

BIODEXA PHARMACEUTICALS PLC ADR

0,876

-4,99 %

GRANITE REAL ESTATE INVESTMENT TRUST UTS

42,200

+1,11 %

LAKESHORE BIOPHARMA CO LTD

0,760

+1,33 %

SIFY TECHNOLOGIES LIMITED ADR